Introduction of the pneumococcal conjugate vaccine in humanitarian and fragile contexts: Perspectives from stakeholders in four African countries

被引:0
|
作者
Dhaliwal, Baldeep K. [1 ]
Weeks, Rose [1 ]
Huber, Jasmine [1 ]
Fofana, Aminata [1 ]
Bobe, Mohamed [2 ]
Mbailamen, Antoinette Demian [3 ]
Legge, George [4 ,5 ]
Cisse, Gassim [5 ]
Shet, Anita [1 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, 415 N Washington St 535, Baltimore, MD 21231 USA
[2] Somalia Somaliland Country Off, Save Children, Mogadishu, Somalia
[3] Minist St Publ, Programme Elargi Vaccinat, Ndjamena, Chad
[4] Expanded Programme Immunisat EPI, Natl Minist Hlth, Juba, Sudan
[5] Expanded Programme Immunisat EPI, Minist Hlth & Publ Hyg, Conakry, Guinea
基金
比尔及梅琳达.盖茨基金会;
关键词
Pneumonia; pneumococcal conjugate vaccine; fragile contexts; health policy; decision-making;
D O I
10.1080/21645515.2024.2314828
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Childhood pneumonia causes a significant burden of preventable child morbidity and mortality in Chad, Guinea, Somalia/Somaliland, and South Sudan. Leaders from these countries have committed to reducing this burden and are preparing to introduce the pneumococcal conjugate vaccine (PCV) into their immunization programs. To support long-term sustainability for expected PCV introductions in settings afflicted by prolonged humanitarian crises this research explores national stakeholders' perspectives on contextual factors that may influence optimal vaccine implementation. This qualitative study used purposive sampling to identify and interview stakeholders involved in vaccine decision-making. Interview transcripts were analyzed through the framework method, an approach involving charting data into pre-populated matrices. Findings from interviews with 16 key informants from government, partner organizations, and international health agencies fit within the following four overarching themes: (1) population-level vulnerabilities to pneumonia, exacerbated by climatic risks and low levels of maternal education; (2) disease burden and the interest in enhancing surveillance to monitor vaccine impact and integrate disease control efforts; (3) policy processes, including formalizing vaccine decision-making; and (4) vaccine implementation preparation, including the conduct of robust communication campaigns, training, and cold chain upgrades. This research explores perspectives from leaders in these countries which are at pivotal moments in their journeys toward introducing PCV. Widespread commitment among leaders, in addition to financial support, will facilitate vaccine introduction. Further, fostering a shared understanding among partners about context-specific determinants of program success will help build tailored implementation strategies for each country.
引用
收藏
页数:9
相关论文
共 42 条
  • [21] Prevention of Invasive Pneumococcal Disease Among Black or African American Children With and Without Sickle Cell Disease in the United States After Introduction of 13-Valent Pneumococcal Conjugate Vaccine, 2005 Through 2019
    Payne, Amanda B.
    Gierke, Ryan
    Xing, Wei
    Mcgee, Lesley
    Hulihan, Mary
    Adamkiewicz, Thomas V.
    Kobayashi, Miwako
    Active Bacterial Core Surveillance Team
    PEDIATRIC BLOOD & CANCER, 2025, 72 (03)
  • [22] Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
    Stefan Flasche
    John Ojal
    Olivier Le Polain de Waroux
    Mark Otiende
    Katherine L. O’Brien
    Moses Kiti
    D. James Nokes
    W John Edmunds
    J. Anthony G. Scott
    BMC Medicine, 15
  • [23] Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction
    Gertz, RE
    McEllistrem, MC
    Boxrud, DJ
    Li, ZY
    Sakota, V
    Thompson, TA
    Facklam, RR
    Besser, JM
    Harrison, LH
    Whitney, CG
    Beall, B
    JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (09) : 4194 - 4216
  • [24] Pediatric Bacterial Meningitis Surveillance in Nigeria From 2010 to 2016, Prior to and During the Phased Introduction of the 10-Valent Pneumococcal Conjugate Vaccine
    Tagbo, Beckie N.
    Bancroft, Rowan E.
    Fajolu, Iretiola
    Abdulkadir, Mohammed B.
    Bashir, Muhammad F.
    Okunola, Olusola P.
    Isiaka, Ayodeji H.
    Lawal, Namadi M.
    Edelu, Benedict O.
    Onyejiaka, Ngozi
    Ihuoma, Chinonyerem J.
    Ndu, Florence
    Ozumba, Uchenna C.
    Udeinya, Frances
    Ogunsola, Folasade
    Saka, Aishat O.
    Fadeyi, Abayomi
    Aderibigbe, Sunday A.
    Abdulraheem, Jimoh
    Yusuf, Adamu G.
    Ndow, Peter Sylvanus
    Ogbogu, Philomena
    Kanu, Chinomnso
    Emina, Velly
    Makinwa, Olajumoke J.
    Gehre, Florian
    Yusuf, Kabir
    Braka, Fiona
    Mwenda, Jason M.
    Ticha, Johnson M.
    Nwodo, Dorothy
    Worwui, Archibald
    Biey, Joseph N.
    Kwambana-Adams, Brenda A.
    Antonio, Martin
    CLINICAL INFECTIOUS DISEASES, 2019, 69 : S81 - S88
  • [25] Streptococcus pneumoniae serotypes isolated from the middle ear fluid of Costa Rican children following introduction of the heptavalent pneumococcal conjugate vaccine into a limited population
    Guevara, Silvia
    Abdelnour, Arturo
    Soley, Carolina
    Porat, Nurith
    Dagan, Ron
    Arguedas, Adriano
    VACCINE, 2012, 30 (26) : 3857 - 3861
  • [26] Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013
    Diomande, Fabien V. K.
    Yameogo, Tene M.
    Vannice, Kirsten S.
    Preziosi, Marie-Pierre
    Viviani, Simonetta
    Ouandaogo, Claude-Roger
    Keita, Modibo
    Djingarey, Mamoudou H.
    Mbakuliyemo, Nehemie
    Akanmori, Bartholomew Dicky
    Sow, Samba O.
    Zuber, Patrick L. F.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 : S459 - S466
  • [27] Population impact and effectiveness of sequential 13-valent pneumococcal conjugate and monovalent rotavirus vaccine introduction on infant mortality: prospective birth cohort studies from Malawi
    King, Carina
    Bar-Zeev, Naor
    Phiri, Tambosi
    Beard, James
    Mvula, Hazzie
    Crampin, Amelia
    Heinsbroek, Ellen
    Hungerford, Dan
    Lewckya, Sonia
    Verani, Jennifer
    Whitney, Cynthia
    Costello, Anthony
    Mwansambo, Charles
    Cunliffe, Nigel
    Heyderman, Rob
    French, Neil
    Nakagomi, Osamu
    BMJ GLOBAL HEALTH, 2020, 5 (09):
  • [28] Serotyping and Multilocus Sequence Typing of Streptococcus pneumoniae Isolates from the Blood and Posterior Nares of Japanese Children Prior to the Introduction of 7-Valent Pneumococcal Conjugate Vaccine
    Oishi, Tomohiro
    Wada, Akihito
    Chang, Bin
    Toyabe, Shinichi
    Uchiyama, Makoto
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2011, 64 (04) : 341 - 344
  • [29] Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina
    Lopez, Eduardo L.
    Glatstein, Eduardo
    Ezcurra, Gustavo C.
    Iacono, Marisa
    Teplitz, Eduardo
    Garnero, Analia V.
    Lazzarini, Daniela L.
    Vazquez, Miryan
    Contrini, Maria M.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2018, 7 (01) : 30 - 35
  • [30] Genetic characteristics and antibiotic resistance of Haemophilus influenzae isolates from pediatric patients with acute otitis media after introduction of 13-valent pneumococcal conjugate vaccine in Japan
    Ubukata, Kimiko
    Morozumi, Miyuki
    Sakuma, Megumi
    Adachi, Yoko
    Mokuno, Eriko
    Tajima, Takeshi
    Iwata, Satoshi
    Inagaki, Mikiya
    Kamakazu, Kiyoaki
    Atago, Yoshihiro
    Kakurai, Shinichi
    Iwamoto, Junichi
    Usui, Shinji
    Ooyama, Seizou
    Sugano, Sumio
    Kuroda, Hisashi
    Kamide, Yousuke
    Kamide, Michihiro
    Murakawa, Yasuko
    Kaieda, Satoru
    Kawaziri, Ippei
    Kawai, Akimitsu
    Kikuchi, Yasutake
    Sawaki, Seiji
    Kyou, Koujin
    Kimura, Shigeru
    Kimura, Yasuko
    Kimura, Yutaka
    Sashiyou, Hideyuki
    Yoneya, Hirohide
    Kosaka, Kazumi
    Komeda, Mototane
    Kobayashi, Katsuhiko
    Sakaida, Yudzuru
    Sawada, Shoichi
    Satoh, Tatsuaki
    Satoh, Masami
    Shimizu, Toshiaki
    Kimura, Osamu
    Shimada, Jun
    Hori, Yasutaka
    Sugita, Rinya
    Sugita, Yoshinobu
    Uchizono, Akihiro
    Soeda, Kazuhiro
    Tabuchi, Tomizou
    Matsuoka, Chiharu
    Suzuki, Chiaki
    Chiba, Hideki
    Tsuboi, Yasuhiro
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2019, 25 (09) : 720 - 726